Terns Pharmaceuticals, Inc. (TERN): Price and Financial Metrics Recent IPO
GET POWR RATINGS... FREE!
TERN Stock Price Chart Interactive Chart >
TERN Price/Volume Stats
|Current price||$15.60||52-week high||$28.36|
|Prev. close||$16.25||52-week low||$14.36|
|Day high||$16.44||Avg. volume||138,290|
|50-day MA||$17.30||Dividend yield||N/A|
|200-day MA||$0.00||Market Cap||391.76M|
Terns Pharmaceuticals, Inc. (TERN) Company Bio
Terns Pharmaceuticals, Inc. operates as a biopharmaceutical company. The Company discovers and develops molecularly-targeted and oral molecule drugs for the treatment of liver disease and cancer. Terns Pharmaceuticals serves customers worldwide.
TERN Latest News Stream
|Loading, please wait...|
TERN Latest Social Stream
View Full TERN Social Stream
Latest TERN News From Around the Web
Below are the latest news stories about Terns Pharmaceuticals Inc that investors may wish to consider to help them evaluate TERN as an investment opportunity.
Terns Pharmaceuticals Inc (NASDAQ: TERN) reported top-line results from the Phase 2a LIFT trial of TERN-101, a liver-distributed farnesoid X receptor (FXR) agonist for the treatment of patients with non-alcoholic steatohepatitis (NASH). TERN-101 was generally well-tolerated in the trial with a similar incidence of adverse events across treatment groups. All treatment-related adverse events were mild/moderate with no apparent dose relationship. There were no treatment-related serious adverse even
Terns Reports Positive Top-line Results from Phase 2a LIFT Study of FXR Agonist TERN-101 in Patients with NASH
First FXR agonist trial to demonstrate no discontinuations due to AEs, including pruritus, and both a differentiated pruritus and lipid profile in patients with NASH First 12-week controlled trial in patients with NASH to show significant improvements in corrected T1 (cT1), an imaging marker of liver inflammation and fibrosis linked to clinical outcomes Terns plans to initiate first NASH trial of an FXR agonist (TERN-101) in combination with a THR-β agonist (TERN-501) in 1H22 Company to host con
Terns Pharmaceuticals to Host Conference Call to Discuss Top-line Results from Phase 2a LIFT Study of TERN-101 for Treatment of NASH
FOSTER CITY, Calif., June 13, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, announced that the Company will host a conference call and live webcast on Monday, June 14, 2021 at 8:30 a.m. ET (5:30 a.m. PT) to discuss new top-lin
-Top-line data from the Phase 2a LIFT study of TERN-101 expected in June 2021-FOSTER CITY, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update. “Our development team has continued to rapidly advance our NASH clinical programs, with top-line data for the Phase 2a LIFT study of FXR agonist TERN-101 in NASH now accelerated into June 2021. In the LIFT study, in addition to safety and tolerability, we are a...
Every investor in Terns Pharmaceuticals, Inc. ( NASDAQ:TERN ) should be aware of the most powerful shareholder groups...
TERN Price Returns